Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,06
KB-0,07
PKN64,664,70,77
Msft241,01241,040,26
Nokia4,64154,64452,14
IBM145,88145,92-0,40
Mercedes-Benz Group AG64,5564,563,23
PFE49,3349,34-0,30
30.11.2022 17:21:00
Indexy online
AD Index online
select
AD Index online
 

  • 30.11.2022 17:19:55
Gilead Sciences (GILD.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
85,50 -0,30 -0,26 1 781 122
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 30.11.2022
Popis společnosti
Obecné informace
Název společnostiGilead Sciences, Inc.
TickerGILD
Kmenové akcie:Ordinary Shares
RICGILD.O
ISINUS3755581036
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.09.2022
Počet zaměstnanců k 31.12.2021 14 400
Akcie v oběhu k 31.10.20221 254 243 845
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice333 LAKESIDE DR
MěstoFOSTER CITY
PSČ94404
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 505 743 000
Fax16505789264

Business Summary: Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. The Company is also focused on restoring immune balance with agonists targeting immune inhibitory receptors.
Financial Summary: BRIEF: For the nine months ended 30 September 2022, Gilead Sciences, Inc. revenues decreased 1% to $19.89B. Net income decreased 49% to $2.95B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Selling, general and administrative expe increase of 44% to $3.65B (expense), Acquired in-process research and develop increase from $177M to $778M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 30.11.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerDaniel O'Day5701.03.201901.03.2019
Chief Financial OfficerAndrew Dickinson5204.06.2018
Executive Vice President - Corporate Affairs, General Counsel, Corporate SecretaryDeborah Telman5701.08.202201.08.2022
Executive Vice President - Pharmaceutical Development and ManufacturingStacey Ma-18.07.202218.07.2022
Executive Vice President - ResearchFlavius Martin-12.04.202112.04.2021
Chief Commercial OfficerJohanna Mercier5201.07.201901.07.2019
Chief Medical OfficerMerdad Parsey5801.11.201901.11.2019